CombYSelect-Based Bispecific Antibodies & Bispecific Antibody-Drug Conjugates

Our proprietary CombYSelect platform enables the rapid and reliable creation of IgG-like bispecific antibodies that target two tumor antigens simultaneously while maintaining a long, natural serum half-life. This approach simplifies therapeutic design, reduces the need for multi- antibody cocktails, and facilitates the engineering of advanced modalitiesโfrom dual-target bispecifics to functional Fc fusion proteinsโsupporting a versatile range of therapeutic designs. CombYSelect is also applicable to other isotypes, paving the way for next-generation, multi- modal therapies.
This platform also drives our bispecific antibody-drug conjugates (BADCs), which deliver potent, highly specific payloadsโincluding cytotoxic agents, 7PB-100, and other innovative small moleculesโdirectly to multiple tumor cells while minimizing side effects on healthy tissue.
Key Advantages:
โข Dual antigen targeting for potent, tumor-specific cell killing
โข Minimal, targeted mutations for rapid development, scalability, and high expression
โข Customizable payloads for diverse cancer types
โข Reduced risk of resistance through dual targeting and multifaceted mechanisms
โข Low off-target toxicity and an enhanced safety profile
Our proprietary CombYSelect platform enables the rapid and reliable creation of IgG-like bispecific antibodies that target two tumor antigens simultaneously while maintaining a long, natural serum half-life. This approach simplifies therapeutic design, reduces the need for multi- antibody cocktails, and facilitates the engineering of advanced modalitiesโfrom dual-target bispecifics to functional Fc fusion proteinsโsupporting a versatile range of therapeutic designs. CombYSelect is also applicable to other isotypes, paving the way for next-generation, multi- modal therapies.
This platform also drives our bispecific antibody-drug conjugates (BADCs), which deliver potent, highly specific payloadsโincluding cytotoxic agents, 7PB-100, and other innovative small moleculesโdirectly to multiple tumor cells while minimizing side effects on healthy tissue.
Key Advantages:
โข Dual antigen targeting for potent, tumor-specific cell killing
โข Minimal, targeted mutations for rapid development, scalability, and high expression
โข Customizable payloads for diverse cancer types
โข Reduced risk of resistance through dual targeting and multifaceted mechanisms
โข Low off-target toxicity and an enhanced safety profile
Our proprietary CombYSelect platform enables the rapid and reliable creation of IgG-like bispecific antibodies that target two tumor antigens simultaneously while maintaining a long, natural serum half-life. This approach simplifies therapeutic design, reduces the need for multi- antibody cocktails, and facilitates the engineering of advanced modalitiesโfrom dual-target bispecifics to functional Fc fusion proteinsโsupporting a versatile range of therapeutic designs. CombYSelect is also applicable to other isotypes, paving the way for next-generation, multi- modal therapies.
This platform also drives our bispecific antibody-drug conjugates (BADCs), which deliver potent, highly specific payloadsโincluding cytotoxic agents, 7PB-100, and other innovative small moleculesโdirectly to multiple tumor cells while minimizing side effects on healthy tissue.
Key Advantages:
โข Dual antigen targeting for potent, tumor-specific cell killing
โข Minimal, targeted mutations for rapid development, scalability, and high expression
โข Customizable payloads for diverse cancer types
โข Reduced risk of resistance through dual targeting and multifaceted mechanisms
โข Low off-target toxicity and an enhanced safety profile

Your Gateway to Precision Cancer Innovation
Have questions or want to know more about our ground breaking targeted cancer therapeutics? Feel free to reach out to our dedicated team.
Interested in unlocking new possibilities? Connect with our team.
Letโs Talk With Us

Your Gateway to Precision Cancer Innovation
Have questions or want to know more about our ground breaking targeted cancer therapeutics? Feel free to reach out to our dedicated team.
Interested in unlocking new possibilities? Connect with our team.
Letโs Talk With Us

Your Gateway to Precision Cancer Innovation
Letโs Talk With Us
Interested in unlocking new possibilities? Connect with our team.